23andMe Challenges a Creaky Regulatory State

Dec. 5 (Bloomberg) -- Let’s agree that 23andMe Inc., the Google-backed company marketing a $99 genetics test that assesses your risk for more than 240 health conditions, didn’t manage its relationship with the Food and Drug Administration well.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.